The long non-coding RNA PCA3 : an update of its functions and clinical applications as a biomarker in prostate cancer

Prostate cancer antigen 3 ( PCA3 ) is an overexpressed prostate long non-coding RNA (lncRNA), transcribed from an intronic region at the long arm of human chromosome 9q21–22. It has been described that PCA3 modulates prostate cancer (PCa) cell survival through modulating androgen receptor (AR) signa...

Full description

Saved in:
Bibliographic Details
Published inOncotarget Vol. 10; no. 61; pp. 6589 - 6603
Main Authors Lemos, Ana Emília Goulart, Matos, Aline da Rocha, Ferreira, Luciana Bueno, Gimba, Etel Rodrigues Pereira
Format Journal Article
LanguageEnglish
Published Impact Journals LLC 12.11.2019
Subjects
Review
Online AccessGet full text

Cover

Abstract Prostate cancer antigen 3 ( PCA3 ) is an overexpressed prostate long non-coding RNA (lncRNA), transcribed from an intronic region at the long arm of human chromosome 9q21–22. It has been described that PCA3 modulates prostate cancer (PCa) cell survival through modulating androgen receptor (AR) signaling, besides controlling the expression of several androgen responsive and cancer-related genes, including epithelial–mesenchymal transition (EMT) markers and those regulating gene expression and cell signaling. Also, PCA3 urine levels have been successfully used as a PCa diagnostic biomarker. In this review, we have highlighted recent findings regarding PCA3 , addressing its gene structure, putative applications as a biomarker, a proposed origin of this lncRNA, roles in PCa biology and expression patterns. We also updated data regarding PCA3 interactions with cancer-related miRNAs and expression in other tissues and diseases beyond the prostate. Altogether, literature data indicate aberrant expression and dysregulated activity of PCA3 , suggesting PCA3 as a promising relevant target that should be even further evaluated on its applicability for PCa detection and management.
AbstractList Prostate cancer antigen 3 ( PCA3 ) is an overexpressed prostate long non-coding RNA (lncRNA), transcribed from an intronic region at the long arm of human chromosome 9q21–22. It has been described that PCA3 modulates prostate cancer (PCa) cell survival through modulating androgen receptor (AR) signaling, besides controlling the expression of several androgen responsive and cancer-related genes, including epithelial–mesenchymal transition (EMT) markers and those regulating gene expression and cell signaling. Also, PCA3 urine levels have been successfully used as a PCa diagnostic biomarker. In this review, we have highlighted recent findings regarding PCA3 , addressing its gene structure, putative applications as a biomarker, a proposed origin of this lncRNA, roles in PCa biology and expression patterns. We also updated data regarding PCA3 interactions with cancer-related miRNAs and expression in other tissues and diseases beyond the prostate. Altogether, literature data indicate aberrant expression and dysregulated activity of PCA3 , suggesting PCA3 as a promising relevant target that should be even further evaluated on its applicability for PCa detection and management.
Author Gimba, Etel Rodrigues Pereira
Lemos, Ana Emília Goulart
Matos, Aline da Rocha
Ferreira, Luciana Bueno
Author_xml – sequence: 1
  givenname: Ana Emília Goulart
  surname: Lemos
  fullname: Lemos, Ana Emília Goulart
  organization: Departamento de Epidemiologia e Métodos Quantitativos em Saúde, Escola Nacional de Saúde Pública/Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil, Programa de Pós-Graduação em Ciências Biomédicas – Fisiologia e Farmacologia, Universidade Federal Fluminense, Rio de Janeiro, Brazil
– sequence: 2
  givenname: Aline da Rocha
  surname: Matos
  fullname: Matos, Aline da Rocha
  organization: Laboratório de Vírus Respiratórios e do Sarampo, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil
– sequence: 3
  givenname: Luciana Bueno
  surname: Ferreira
  fullname: Ferreira, Luciana Bueno
  organization: Coordenação de Pesquisa, Instituto Nacional do Câncer, Rio de Janeiro, Brazil
– sequence: 4
  givenname: Etel Rodrigues Pereira
  surname: Gimba
  fullname: Gimba, Etel Rodrigues Pereira
  organization: Programa de Pós-Graduação em Ciências Biomédicas – Fisiologia e Farmacologia, Universidade Federal Fluminense, Rio de Janeiro, Brazil, Coordenação de Pesquisa, Instituto Nacional do Câncer, Rio de Janeiro, Brazil, Departamento de Ciências da Natureza (RCN), Instituto de Humanidades e Saúde, Universidade Federal Fluminense, Rio de Janeiro, Brazil
BookMark eNpVkVtr3DAQhUXYkMt2f0De9NgXJ5Zk2Tt9KCxLLoUlCSF9FrI03ij1Sq5kF_LvoyRL24gBHTjDN9KcUzLzwSMhZ6w8Z8ta8IvgTRh13OJ4zhu-rA7ICYMKCi6lmP2nj8kipecyH1k1Sw5H5FiwpuZQlSdkenxC2ge_pRlfmGBdlg-3K3q_Xgn6jWpPp8HqEWnoqBsT7SZvRhd8ypalpnfeGd1TPQx9FnsnF21d2On4CyN1ng4xpPGNYrQ3GL-Qw073CRf7e05-Xl0-rm-Kzd31j_VqUxgOrCo0CGGahlvbIPJadkzIFroOGzS2qgDK1vIWEBhIazlHjh1IXlldCw0WxJx8_-AOU7tDa9CPUfdqiC4_7UUF7dRnx7sntQ1_VL2UALzMgK97QAy_J0yj2rlksO-1xzAlxfMmQdbAZG5lH60m_zVF7P6OYaV6T0z9S0y9JyZeAZlHjjE
CitedBy_id crossref_primary_10_3389_fphar_2024_1383304
crossref_primary_10_1016_j_prp_2023_154666
crossref_primary_10_7554_eLife_81929
crossref_primary_10_3389_fcvm_2021_688546
crossref_primary_10_3390_cancers15164160
crossref_primary_10_1016_j_critrevonc_2024_104275
crossref_primary_10_3390_genes12081124
crossref_primary_10_1007_s11010_024_04933_1
crossref_primary_10_3389_fcell_2021_658346
crossref_primary_10_1016_j_bios_2021_113520
crossref_primary_10_1016_j_cca_2024_117824
crossref_primary_10_3389_fonc_2021_712786
crossref_primary_10_3390_cancers14194760
crossref_primary_10_3390_cancers16091757
crossref_primary_10_3390_ncrna6030025
crossref_primary_10_3390_jcm13103016
crossref_primary_10_1080_21655979_2021_1945991
crossref_primary_10_1186_s12859_021_04282_6
crossref_primary_10_3390_cancers15133433
crossref_primary_10_1016_j_prp_2024_155123
crossref_primary_10_1080_21655979_2021_2019872
crossref_primary_10_1158_0008_5472_CAN_22_3186
crossref_primary_10_3390_ijms22042100
crossref_primary_10_2217_epi_2023_0045
crossref_primary_10_3390_ijms23116281
crossref_primary_10_3390_ijms24087426
crossref_primary_10_3390_mi15050602
crossref_primary_10_3389_fgene_2022_958547
crossref_primary_10_1038_s41467_022_33780_1
crossref_primary_10_1109_TCBB_2021_3113326
crossref_primary_10_1016_j_toxlet_2021_05_006
crossref_primary_10_3389_fmolb_2022_939070
crossref_primary_10_1016_j_canlet_2022_215619
crossref_primary_10_3390_cancers14030755
crossref_primary_10_1007_s12668_024_01459_0
crossref_primary_10_1038_s41419_020_02954_4
crossref_primary_10_1016_j_ijbiomac_2022_02_082
crossref_primary_10_1089_gtmb_2022_0086
crossref_primary_10_1136_ijgc_2022_003702
crossref_primary_10_1016_j_urolonc_2021_11_012
crossref_primary_10_1016_j_critrevonc_2024_104290
crossref_primary_10_1186_s12943_020_01219_0
crossref_primary_10_1038_s41525_024_00401_3
crossref_primary_10_3390_ijms242316600
crossref_primary_10_3389_fonc_2023_1240868
crossref_primary_10_2174_1871520621666210308101029
crossref_primary_10_1080_14737159_2020_1842199
crossref_primary_10_1016_j_urolonc_2020_06_003
crossref_primary_10_1186_s12967_020_02281_4
crossref_primary_10_1016_j_ncrna_2024_06_015
crossref_primary_10_7554_eLife_84263
crossref_primary_10_3390_diagnostics13213350
crossref_primary_10_1002_ijc_34282
Cites_doi 10.1007/s00345-014-1251-3
10.1007/s00345-015-1643-z
10.1007/s00018-017-2626-6
10.1016/j.molcel.2013.08.027
10.1111/j.1464-410X.2011.10377.x
10.3892/or.2015.4266
10.1111/bju.13318
10.1001/jamaoncol.2017.0177
10.3390/ijms140611347
10.1373/clinchem.2005.063289
10.1007/s13277-016-5450-y
10.1016/j.gene.2017.08.027
10.2298/ACI1101081P
10.1371/journal.pone.0004995
10.18632/oncotarget.14501
10.1111/j.1464-410X.2005.05943.x
10.3892/or.2016.4663
10.1016/j.juro.2009.10.003
10.18632/oncotarget.14131
10.1002/pros.20781
10.1016/j.eururo.2010.10.024
10.1016/j.eururo.2010.11.044
10.1002/jcp.27980
10.1038/nature12548
10.1002/pros.21032
10.1371/journal.pgen.1003470
10.1128/JVI.00608-15
10.1016/j.eururo.2013.05.049
10.1002/cncr.29611
10.1016/j.juro.2008.07.060
10.1016/j.juro.2008.01.013
10.1080/13547500902807306
10.1016/j.juro.2012.04.143
10.1038/pcan.2017.16
10.1002/pros.21457
10.1371/journal.pone.0154507
10.1016/j.urology.2006.12.014
10.1016/j.patol.2018.04.003
10.3390/ijms140917767
10.1002/pros.21040
10.1111/bju.14041
10.1186/1479-5876-7-4
10.18632/oncotarget.15133
10.1016/j.juro.2010.11.072
10.1038/nrurol.2017.70
10.1016/j.cmonc.2012.05.008
10.18632/oncotarget.6158
10.1016/j.juro.2010.06.098
10.1002/pros.22546
10.1016/S0090-4295(03)00759-3
10.1007/s13277-016-5012-3
10.1186/1471-2407-12-507
10.1016/j.eururo.2010.06.039
10.1373/clinchem.2012.195560
10.21873/anticanres.11733
10.1016/j.juro.2011.10.133
10.1038/ki.2010.106
10.1073/pnas.1507882112
10.1016/j.nano.2011.11.009
10.1002/wrna.1463
10.3978/j.issn.1000-9604.2016.01.05
10.1158/0008-5472.CAN-16-2634
10.1016/j.urolonc.2012.05.012
10.1038/modpathol.3800963
10.5858/arpa.2017-0185-OA
10.1002/pros.21011
10.1016/j.gpb.2015.09.006
10.1038/pcan.2011.52
10.1016/j.eururo.2008.06.071
10.3390/ijms150813299
10.1016/j.juro.2007.11.038
10.1016/j.eururo.2009.03.029
10.1016/j.biopha.2017.01.004
10.1111/j.1464-410X.2012.11645.x
10.1111/bju.12542
10.1056/NEJMoa031918
10.1002/pros.21390
10.15252/emmm.201708072
10.1111/j.1464-410X.2011.10682.x
10.1016/j.cell.2011.07.014
10.1016/j.clinbiochem.2008.06.013
10.1038/sj.onc.1210070
10.1186/s13046-015-0127-8
10.1038/srep12090
10.1111/cas.12441
10.1097/MD.0000000000012806
10.1016/j.biopha.2017.10.083
10.1111/j.1464-410X.2010.09286.x
10.1016/j.eururo.2012.11.014
ContentType Journal Article
Copyright Copyright: © 2019 Lemos et al. 2019
Copyright_xml – notice: Copyright: © 2019 Lemos et al. 2019
DBID AAYXX
CITATION
7X8
5PM
DOI 10.18632/oncotarget.27284
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 1949-2553
EndPage 6603
ExternalDocumentID 10_18632_oncotarget_27284
GroupedDBID ---
53G
AAYXX
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
FRJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
7X8
5PM
ID FETCH-LOGICAL-c2914-a933c772dd7ee265f135b9ffe7ecd44990bd2b9e9195dd22e2ef9524da63a9d93
IEDL.DBID RPM
ISSN 1949-2553
IngestDate Tue Sep 17 21:27:10 EDT 2024
Fri Aug 16 10:34:50 EDT 2024
Fri Aug 23 01:32:14 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 61
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2914-a933c772dd7ee265f135b9ffe7ecd44990bd2b9e9195dd22e2ef9524da63a9d93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859920/
PMID 31762940
PQID 2317956915
PQPubID 23479
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6859920
proquest_miscellaneous_2317956915
crossref_primary_10_18632_oncotarget_27284
PublicationCentury 2000
PublicationDate 20191112
PublicationDateYYYYMMDD 2019-11-12
PublicationDate_xml – month: 11
  year: 2019
  text: 20191112
  day: 12
PublicationDecade 2010
PublicationTitle Oncotarget
PublicationYear 2019
Publisher Impact Journals LLC
Publisher_xml – name: Impact Journals LLC
References Puig (78) 2019; 52
Marks (45) 2009; 56
Isaacs (1) 1999; 59
Jarrard (28) 2013; 189
Moul (67) 2000; 60
Damiano (71) 2016; 34
Wang (74) 2015; 8
Fisher (62) 2007; 26
de la Taille (42) 2011; 59
Feschotte (9) 2013; 9
de la Taille (51) 2012; 110
Hu (23) 2017; 87
He (21) 2017; 8
Terracciano (70) 2015; 35
Macairan (30) 2006; 52
Vlaeminck-Guillem (73) 2014; 15
Rittenhouse (39) 2008; 180
Chang (91) 2013; 500
Tetu (4) 2007; 20
Lotan (69) 2013; 64
Ruffion (82) 2011; 185
Randone (50) 2012; 110
Meng (65) 2018; 142
Benson (88) 2016; 11
Vlaeminck-Guillem (54) 2013; 14
Fracchia (52) 2012; 9
Zhang (10) 2016
Gimba (12) 2012; 12
Pavlovich (76) 2017; 20
Gardiner (6) 2009; 4
Dahiya (94) 2018; 75
Mandal (2) 2017; 77
Goulart (24) 2008; 41
Fullwood (93) 2016; 14
Djurasic (27) 2011; 58
Pandolfi (16) 2011; 146
Schalken (29) 2012; 187
Hu (92) 2015; 6
Goulart (5) 2015; 5
Clawson (56) 2012; 8
Sokoll (47) 2010; 183
Groskopf (36) 2010; 184
Karnes (79) 2017; 8
Kagan (63) 2017; 3
Hulsbergen-van de Kaa (72) 2014; 65
Mulders (81) 2013; 14
Salmeron (13) 2015; 112
Haese (40) 2011; 59
Schalken (48) 2010; 70
Sednaoui (49) 2012; 72
Flemington (11) 2015; 89
Groskopf (41) 2008; 179
Groskopf (34) 2007; 69
Kong (55) 2015; 34
Marberger (37) 2012; 109
Friedersdorff (60) 2013; 59
Albulescu (86) 2017; 8
Gimba (14) 2016; 37
van Gils (38) 2008; 54
Planas (66) 2011; 71
Damiano (80) 2016; 118
Hessels (31) 2010; 58
Russo (87) 2010; 78
Schalken (7) 2010; 70
Coltman (32) 2004; 350
Sivkov (58) 2015
Fenner (35) 2017; 14
Wang (18) 2019; 234
Stolz (25) 2010; 30
Talesa (68) 2009; 14
Seki (20) 2014; 105
Denton (59) 2015; 121
Schalken (89) 2005; 96
Verhaegh (3) 2003; 62
Gorospe (95) 2018; 9
Yang (19) 2016; 35
Zhang (22) 2018; 97
Vlaeminck-Guillem (53) 2014; 32
Dujardin (77) 2018; 121
Schalken (84) 2009; 69
Zhao (90) 2017; 633
Pasqualini (8) 2017; 9
Shinohara (43) 2012; 15
Schalken (61) 2013; 73
Clayton (85) 2009; 7
Xie (64) 2018; 97
Cigliana (75) 2015; 34
Wang (57) 2016; 28
Babaian (44) 2008; 179
de la Taille (83) 2014; 114
Schalken (46) 2008; 68
Gregory (17) 2013; 52
Khan (26) 2013; 31
Stillebroer (33) 2010; 106
Gezer (15) 2017; 37
References_xml – volume: 32
  start-page: 917
  year: 2014
  ident: 53
  article-title: Additional value of PCA3 density to predict initial prostate biopsy outcome
  publication-title: World J Urol
  doi: 10.1007/s00345-014-1251-3
  contributor:
    fullname: Vlaeminck-Guillem
– volume: 34
  start-page: 485
  year: 2016
  ident: 71
  article-title: PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance
  publication-title: World J Urol
  doi: 10.1007/s00345-015-1643-z
  contributor:
    fullname: Damiano
– volume: 75
  start-page: 467
  year: 2018
  ident: 94
  article-title: Interaction and cross-talk between non-coding RNAs
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-017-2626-6
  contributor:
    fullname: Dahiya
– volume: 52
  start-page: 101
  year: 2013
  ident: 17
  article-title: The imprinted H19 lncRNA antagonizes let-7 microRNAs
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2013.08.027
  contributor:
    fullname: Gregory
– volume: 109
  start-page: 360
  year: 2012
  ident: 37
  article-title: The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10377.x
  contributor:
    fullname: Marberger
– volume: 34
  start-page: 2439
  year: 2015
  ident: 55
  article-title: Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequencespecific RNA capture
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.4266
  contributor:
    fullname: Kong
– volume: 118
  start-page: 527
  year: 2016
  ident: 80
  article-title: In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance
  publication-title: BJU Int
  doi: 10.1111/bju.13318
  contributor:
    fullname: Damiano
– volume: 3
  start-page: 1085
  year: 2017
  ident: 63
  article-title: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.0177
  contributor:
    fullname: Kagan
– volume: 14
  start-page: 11347
  year: 2013
  ident: 81
  article-title: Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms140611347
  contributor:
    fullname: Mulders
– volume: 52
  start-page: 1089
  year: 2006
  ident: 30
  article-title: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2005.063289
  contributor:
    fullname: Macairan
– year: 2016
  ident: 10
  article-title: Snail-activated long non-coding RNA PCA3 up-regulates PRKD3 expression by miR-1261 sponging, thereby promotes invasion and migration of prostate cancer cells
  publication-title: Tumour Biol
  doi: 10.1007/s13277-016-5450-y
  contributor:
    fullname: Zhang
– start-page: 46
  year: 2015
  ident: 58
  article-title: [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER]. [Article in Russian]
  publication-title: Urologiia
  contributor:
    fullname: Sivkov
– volume: 633
  start-page: 42
  year: 2017
  ident: 90
  article-title: The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression
  publication-title: Gene
  doi: 10.1016/j.gene.2017.08.027
  contributor:
    fullname: Zhao
– volume: 58
  start-page: 81
  year: 2011
  ident: 27
  article-title: The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model
  publication-title: Acta Chir Iugosl
  doi: 10.2298/ACI1101081P
  contributor:
    fullname: Djurasic
– volume: 35
  start-page: 1017
  year: 2015
  ident: 70
  article-title: Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine
  publication-title: Anticancer Res
  contributor:
    fullname: Terracciano
– volume: 4
  start-page: e4995
  year: 2009
  ident: 6
  article-title: New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0004995
  contributor:
    fullname: Gardiner
– volume: 8
  start-page: 18497
  year: 2017
  ident: 86
  article-title: Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14501
  contributor:
    fullname: Albulescu
– volume: 96
  start-page: 23
  year: 2005
  ident: 89
  article-title: Validation of molecular targets in prostate cancer
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2005.05943.x
  contributor:
    fullname: Schalken
– volume: 35
  start-page: 2859
  year: 2016
  ident: 19
  article-title: MiR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4663
  contributor:
    fullname: Yang
– volume: 183
  start-page: 534
  year: 2010
  ident: 47
  article-title: Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program
  publication-title: J Urol
  doi: 10.1016/j.juro.2009.10.003
  contributor:
    fullname: Sokoll
– volume: 8
  start-page: 8162
  year: 2017
  ident: 21
  article-title: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14131
  contributor:
    fullname: He
– volume: 59
  start-page: 5975
  year: 1999
  ident: 1
  article-title: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer
  publication-title: Cancer Res
  contributor:
    fullname: Isaacs
– volume: 68
  start-page: 1215
  year: 2008
  ident: 46
  article-title: Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results
  publication-title: Prostate
  doi: 10.1002/pros.20781
  contributor:
    fullname: Schalken
– volume: 59
  start-page: 96
  year: 2011
  ident: 40
  article-title: Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.10.024
  contributor:
    fullname: Haese
– volume: 59
  start-page: 422
  year: 2011
  ident: 42
  article-title: Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.11.044
  contributor:
    fullname: de la Taille
– volume: 234
  start-page: 13097
  year: 2019
  ident: 18
  article-title: Long noncoding RNA PCA3 regulates prostate cancer through sponging miR-218-5p and modulating high mobility group box 1
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27980
  contributor:
    fullname: Wang
– volume: 500
  start-page: 536
  year: 2013
  ident: 91
  article-title: Gene regulation: Long RNAs wire up cancer growth
  publication-title: Nature
  doi: 10.1038/nature12548
  contributor:
    fullname: Chang
– volume: 70
  start-page: 10
  year: 2010
  ident: 48
  article-title: Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer
  publication-title: Prostate
  doi: 10.1002/pros.21032
  contributor:
    fullname: Schalken
– volume: 9
  start-page: e1003470
  year: 2013
  ident: 9
  article-title: Transposable elements are major contributors to the origin, diversification, and regulation of vertebrate long noncoding RNAs
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1003470
  contributor:
    fullname: Feschotte
– volume: 89
  start-page: 7120
  year: 2015
  ident: 11
  article-title: New Noncoding Lytic Transcripts Derived from the Epstein-Barr Virus Latency Origin of Replication, oriP, Are Hyperedited, Bind the Paraspeckle Protein, NONO/p54nrb, and Support Viral Lytic Transcription
  publication-title: J Virol
  doi: 10.1128/JVI.00608-15
  contributor:
    fullname: Flemington
– volume: 60
  start-page: 6568
  year: 2000
  ident: 67
  article-title: PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer
  publication-title: Cancer Res
  contributor:
    fullname: Moul
– volume: 64
  start-page: 876
  year: 2013
  ident: 69
  article-title: Systematic review of complications of prostate biopsy
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2013.05.049
  contributor:
    fullname: Lotan
– volume: 121
  start-page: 4071
  year: 2015
  ident: 59
  article-title: Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy
  publication-title: Cancer
  doi: 10.1002/cncr.29611
  contributor:
    fullname: Denton
– volume: 180
  start-page: 1975
  year: 2008
  ident: 39
  article-title: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume
  publication-title: J Urol
  doi: 10.1016/j.juro.2008.07.060
  contributor:
    fullname: Rittenhouse
– volume: 30
  start-page: 665
  year: 2010
  ident: 25
  article-title: Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis
  publication-title: Anticancer Res
  contributor:
    fullname: Stolz
– volume: 179
  start-page: 1804
  year: 2008
  ident: 44
  article-title: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance
  publication-title: J Urol
  doi: 10.1016/j.juro.2008.01.013
  contributor:
    fullname: Babaian
– volume: 14
  start-page: 235
  year: 2009
  ident: 68
  article-title: The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer
  publication-title: Biomarkers
  doi: 10.1080/13547500902807306
  contributor:
    fullname: Talesa
– volume: 189
  start-page: 422
  year: 2013
  ident: 28
  article-title: Toward the detection of prostate cancer in urine: a critical analysis
  publication-title: J Urol
  doi: 10.1016/j.juro.2012.04.143
  contributor:
    fullname: Jarrard
– volume: 20
  start-page: 339
  year: 2017
  ident: 76
  article-title: Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2017.16
  contributor:
    fullname: Pavlovich
– volume: 72
  start-page: 549
  year: 2012
  ident: 49
  article-title: Chronic prostatitis does not influence urinary PCA3 score
  publication-title: Prostate
  doi: 10.1002/pros.21457
  contributor:
    fullname: Sednaoui
– volume: 11
  start-page: e0154507
  year: 2016
  ident: 88
  article-title: Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0154507
  contributor:
    fullname: Benson
– volume: 69
  start-page: 532
  year: 2007
  ident: 34
  article-title: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
  publication-title: Urology
  doi: 10.1016/j.urology.2006.12.014
  contributor:
    fullname: Groskopf
– volume: 52
  start-page: 20
  year: 2019
  ident: 78
  article-title: Correlation of mRNA-PCA3 urine levels with the new grading system in prostate cancer
  publication-title: Rev Esp Patol
  doi: 10.1016/j.patol.2018.04.003
  contributor:
    fullname: Puig
– volume: 14
  start-page: 17767
  year: 2013
  ident: 54
  article-title: PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms140917767
  contributor:
    fullname: Vlaeminck-Guillem
– volume: 70
  start-page: 70
  year: 2010
  ident: 7
  article-title: Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer
  publication-title: Prostate
  doi: 10.1002/pros.21040
  contributor:
    fullname: Schalken
– volume: 121
  start-page: 399
  year: 2018
  ident: 77
  article-title: Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5alpha-reductase inhibitors
  publication-title: BJU Int
  doi: 10.1111/bju.14041
  contributor:
    fullname: Dujardin
– volume: 7
  start-page: 4
  year: 2009
  ident: 85
  article-title: Can urinary exosomes act as treatment response markers in prostate cancer?
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-7-4
  contributor:
    fullname: Clayton
– volume: 8
  start-page: 50804
  year: 2017
  ident: 79
  article-title: Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15133
  contributor:
    fullname: Karnes
– volume: 185
  start-page: 1234
  year: 2011
  ident: 82
  article-title: Urinary PCA3 score predicts prostate cancer multifocality
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.11.072
  contributor:
    fullname: Ruffion
– volume: 14
  start-page: 390
  year: 2017
  ident: 35
  article-title: Prostate cancer: PCA3 as a Grade Reclassification Predictor
  publication-title: Nat Rev Urol
  doi: 10.1038/nrurol.2017.70
  contributor:
    fullname: Fenner
– volume: 9
  start-page: 243
  year: 2012
  ident: 52
  article-title: PCA3 permutation increases the prostate biopsy yield
  publication-title: Community Oncol
  doi: 10.1016/j.cmonc.2012.05.008
  contributor:
    fullname: Fracchia
– volume: 6
  start-page: 37043
  year: 2015
  ident: 92
  article-title: Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6158
  contributor:
    fullname: Hu
– volume: 184
  start-page: 1947
  year: 2010
  ident: 36
  article-title: PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.06.098
  contributor:
    fullname: Groskopf
– volume: 73
  start-page: 113
  year: 2013
  ident: 61
  article-title: Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis
  publication-title: Prostate
  doi: 10.1002/pros.22546
  contributor:
    fullname: Schalken
– volume: 62
  start-page: 34
  year: 2003
  ident: 3
  article-title: New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene
  publication-title: Urology
  doi: 10.1016/S0090-4295(03)00759-3
  contributor:
    fullname: Verhaegh
– volume: 37
  start-page: 11339
  year: 2016
  ident: 14
  article-title: PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells
  publication-title: Tumour Biol
  doi: 10.1007/s13277-016-5012-3
  contributor:
    fullname: Gimba
– volume: 12
  start-page: 507
  year: 2012
  ident: 12
  article-title: PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-12-507
  contributor:
    fullname: Gimba
– volume: 58
  start-page: 475
  year: 2010
  ident: 31
  article-title: Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.06.039
  contributor:
    fullname: Hessels
– volume: 59
  start-page: 280
  year: 2013
  ident: 60
  article-title: Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2012.195560
  contributor:
    fullname: Friedersdorff
– volume: 37
  start-page: 3631
  year: 2017
  ident: 15
  article-title: PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.11733
  contributor:
    fullname: Gezer
– volume: 187
  start-page: 795
  year: 2012
  ident: 29
  article-title: Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion
  publication-title: J Urol
  doi: 10.1016/j.juro.2011.10.133
  contributor:
    fullname: Schalken
– volume: 78
  start-page: 191
  year: 2010
  ident: 87
  article-title: Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease
  publication-title: Kidney Int
  doi: 10.1038/ki.2010.106
  contributor:
    fullname: Russo
– volume: 112
  start-page: 8403
  year: 2015
  ident: 13
  article-title: PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.1507882112
  contributor:
    fullname: Salmeron
– volume: 8
  start-page: 1017
  year: 2012
  ident: 56
  article-title: Nanoresonator chip-based RNA sensor strategy for detection of circulating tumor cells: response using PCA3 as a prostate cancer marker
  publication-title: Nanomedicine
  doi: 10.1016/j.nano.2011.11.009
  contributor:
    fullname: Clawson
– volume: 9
  year: 2018
  ident: 95
  article-title: Noncoding RNAs in Alzheimer's disease
  publication-title: Wiley Interdiscip Rev RNA
  doi: 10.1002/wrna.1463
  contributor:
    fullname: Gorospe
– volume: 28
  start-page: 65
  year: 2016
  ident: 57
  article-title: PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer
  publication-title: Chin J Cancer Res
  doi: 10.3978/j.issn.1000-9604.2016.01.05
  contributor:
    fullname: Wang
– volume: 8
  start-page: 16606
  year: 2015
  ident: 74
  article-title: High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients
  publication-title: Int J Clin Exp Med
  contributor:
    fullname: Wang
– volume: 77
  start-page: 3965
  year: 2017
  ident: 2
  article-title: Long Noncoding RNA and Cancer: A New Paradigm
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2634
  contributor:
    fullname: Mandal
– volume: 31
  start-page: 1408
  year: 2013
  ident: 26
  article-title: Defining prostate cancer risk before prostate biopsy
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2012.05.012
  contributor:
    fullname: Khan
– volume: 20
  start-page: 1121
  year: 2007
  ident: 4
  article-title: Identification of PCA3 (DD3) in prostatic carcinoma byhybridization
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.3800963
  contributor:
    fullname: Tetu
– volume: 142
  start-page: 1106
  year: 2018
  ident: 65
  article-title: Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2017-0185-OA
  contributor:
    fullname: Meng
– volume: 69
  start-page: 1624
  year: 2009
  ident: 84
  article-title: Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study
  publication-title: Prostate
  doi: 10.1002/pros.21011
  contributor:
    fullname: Schalken
– volume: 14
  start-page: 42
  year: 2016
  ident: 93
  article-title: Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer
  publication-title: Genomics Proteomics Bioinformatics
  doi: 10.1016/j.gpb.2015.09.006
  contributor:
    fullname: Fullwood
– volume: 15
  start-page: 100
  year: 2012
  ident: 43
  article-title: Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2011.52
  contributor:
    fullname: Shinohara
– volume: 54
  start-page: 1081
  year: 2008
  ident: 38
  article-title: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2008.06.071
  contributor:
    fullname: van Gils
– volume: 15
  start-page: 13299
  year: 2014
  ident: 73
  article-title: Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms150813299
  contributor:
    fullname: Vlaeminck-Guillem
– volume: 179
  start-page: 1587
  year: 2008
  ident: 41
  article-title: PCA3: a molecular urine assay for predicting prostate biopsy outcome
  publication-title: J Urol
  doi: 10.1016/j.juro.2007.11.038
  contributor:
    fullname: Groskopf
– volume: 56
  start-page: 659
  year: 2009
  ident: 45
  article-title: Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2009.03.029
  contributor:
    fullname: Marks
– volume: 87
  start-page: 683
  year: 2017
  ident: 23
  article-title: Long non-coding RNA CCAT1 promotes human retinoblastoma SO-RB50 and Y79 cells through negative regulation of miR-218-5p
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2017.01.004
  contributor:
    fullname: Hu
– volume: 110
  start-page: E778
  year: 2012
  ident: 50
  article-title: Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11645.x
  contributor:
    fullname: Randone
– volume: 114
  start-page: 608
  year: 2014
  ident: 83
  article-title: Triptocare Study Group. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer
  publication-title: BJU Int
  doi: 10.1111/bju.12542
  contributor:
    fullname: de la Taille
– volume: 350
  start-page: 2239
  year: 2004
  ident: 32
  article-title: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa031918
  contributor:
    fullname: Coltman
– volume: 71
  start-page: 1736
  year: 2011
  ident: 66
  article-title: A three-gene panel on urine increases PSA specificity in the detection of prostate cancer
  publication-title: Prostate
  doi: 10.1002/pros.21390
  contributor:
    fullname: Planas
– volume: 9
  start-page: 1327
  year: 2017
  ident: 8
  article-title: Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses
  publication-title: EMBO Mol Med
  doi: 10.15252/emmm.201708072
  contributor:
    fullname: Pasqualini
– volume: 110
  start-page: 43
  year: 2012
  ident: 51
  article-title: The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10682.x
  contributor:
    fullname: de la Taille
– volume: 146
  start-page: 353
  year: 2011
  ident: 16
  article-title: A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?
  publication-title: Cell
  doi: 10.1016/j.cell.2011.07.014
  contributor:
    fullname: Pandolfi
– volume: 41
  start-page: 1191
  year: 2008
  ident: 24
  article-title: Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis
  publication-title: Clin Biochem
  doi: 10.1016/j.clinbiochem.2008.06.013
  contributor:
    fullname: Goulart
– volume: 26
  start-page: 2667
  year: 2007
  ident: 62
  article-title: Diversity of TMPRSS2-ERG fusion transcripts in the human prostate
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210070
  contributor:
    fullname: Fisher
– volume: 34
  start-page: 15
  year: 2015
  ident: 75
  article-title: PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-015-0127-8
  contributor:
    fullname: Cigliana
– volume: 5
  start-page: 12090
  year: 2015
  ident: 5
  article-title: Prostate-specific RNA aptamer: promising nucleic acid antibody-like cancer detection
  publication-title: Sci Rep
  doi: 10.1038/srep12090
  contributor:
    fullname: Goulart
– volume: 105
  start-page: 802
  year: 2014
  ident: 20
  article-title: Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer
  publication-title: Cancer Sci
  doi: 10.1111/cas.12441
  contributor:
    fullname: Seki
– volume: 97
  start-page: e12806
  year: 2018
  ident: 64
  article-title: Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000012806
  contributor:
    fullname: Xie
– volume: 97
  start-page: 543
  year: 2018
  ident: 22
  article-title: The long non-coding RNA MALAT1 interacted with miR-218 modulates choriocarcinoma growth by targeting Fbxw8
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2017.10.083
  contributor:
    fullname: Zhang
– volume: 106
  start-page: 1143
  year: 2010
  ident: 33
  article-title: The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2010.09286.x
  contributor:
    fullname: Stillebroer
– volume: 65
  start-page: 534
  year: 2014
  ident: 72
  article-title: Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2012.11.014
  contributor:
    fullname: Hulsbergen-van de Kaa
SSID ssj0000547829
Score 2.5127501
Snippet Prostate cancer antigen 3 ( PCA3 ) is an overexpressed prostate long non-coding RNA (lncRNA), transcribed from an intronic region at the long arm of human...
SourceID pubmedcentral
proquest
crossref
SourceType Open Access Repository
Aggregation Database
StartPage 6589
SubjectTerms Review
SummonAdditionalLinks – databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSxxBEG6MgngJEZWoSSjBkzC606_ZCoSwiCKCIiEL3oaefiQLMrPuA5J_n6rZ2bgLnoS5NV0wX1d3fdVdDyFOoyucqVSVWYtFprVyGboCMytTpfLg-6q9yr67tzdDfftoHjfEsr1VB-D0VdeO-0kNJ0_nf57_fqcN_403fN8qedFwHYM2cPpcFnTevhNbUivNCn_Xsf1FqW9N9hC7t81XZ-6IbTKoViJfhqwaqhf2uR47uWKMrj-I9x2LhMFi2XfFRqz3xIyWHJ6a-heQS5_5hq0S_LgfwMPlQH0FV8N8zP49NAlGsymwSWu1joYCLFMkYfVJGxx9wCn6HMUzgVENY04TYSme9WWyL4bXVz8vb7KuqULmJeY6c6iUJ0odQhGjtCblylSYUiyiD5r8n14VZIURczQhSBllTGikDs4qhwHVgdikv4gfBUREr3xyeZU8l2VD4_KktEqmRyK0ORRnSwTL8aJ2Rsk-ByNfviBftsgfipMlxiVpOD9buDo282lJDLQgLw5zElisgf9fKtfIXh-pR7_bWtm2bxBl7-jNM4_FDnEk5PTDXH4Sm7PJPH4mHjKrvrTa9Q-P4uO9
  priority: 102
  providerName: Scholars Portal
Title The long non-coding RNA PCA3 : an update of its functions and clinical applications as a biomarker in prostate cancer
URI https://search.proquest.com/docview/2317956915
https://pubmed.ncbi.nlm.nih.gov/PMC6859920
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9tAEF3iHEoupaUtTduEKfRUkO399uRmTNNQcAilAd_EfraGRDKO_f87K1uNfS0IXRYN0uihmbfzZsTYl-Ss0176yhi0lVLSVegsVkZkL3kME9ltZc9vzc29-rHQixOm-16YTrQf_HLYPDwOm-WfTlu5egyjXic2upvPzEQjivFowAZWygOKvhvorSjq4b6COTFSjNoy56ATVg-Fpe_xGXtBYdMILFseh-HoOcc8VkgehJzrV-zlPleE6e6eXrOT1LxhG3qx8NA2v4GIexXaEnvg5-0U7mZTeQWuge2qsHhoMyw3T1ACV4ctWorQN0LCYeEaHB1QGvGLVmcNywZWpRmkWAkFFeu37P7626_ZTbX_dUIVBHJVOZQyUOIco01JGJ251B5zTjaFqIjljH0UHhNy1DEKkUTKqIWKzkiHEeU7dkpPkd4zSIhBhuy4z6EMX0PteJZKZj0mE0qfs6-9B-vVbkJGXZhF8Xz97Pm68_w5-9z7uCYcl-KEa1K7faopz7TE1ZCTQXvk_H9WyyTs4xUCSDcRew-ID_995Ud2RpkQliZDLj6x0816my4o29j4Szb4vuB0nqvJZYe0v9aL3Cw
link.rule.ids 230,315,733,786,790,891,2236,24346,27957,27958,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEF2VIkEvFASI0gKLxAnJTrxfzvQWRa0CNFGFWtSbtZ8lol1HqXPpr2fWiWnCDSTfVh559WY9M7tv3hLyyetSS8NNphSUmRBcZ6BLyBQLhhfODni7lT2ZqvGl-Holr3aI7HphWtK-NbM83tzmcfaz5VbOb22v44n1zicjNZAArN97RB7jemXlRpG-kvQWGPdgfYY5UJz16qR00FKrc1biH3mPPMHAqRikTY_NgPSQZW5zJDeCzuk--dF97opr8itfNia3938pOf7zfJ6TZ-s0lA5Xwy_Ijo8vSYM-Q2_qeE1jHTNbp7BGv0-H9Hw05MdUR7qcpw0CWgc6a-5oiomt2-KQo12PJd08E6caH5p6_BMNaEFnkc5Tn0myYpPDLV6Ry9OTi9E4W9_KkFkGhcg0cG4xJ3eu9J4pGQouDYTgS2-dwAKqbxwz4KEA6RxjnvkAkgmnFdfggL8muzgL_4ZQD2C5DbowwSZdN5C6CFzwIPtoQsgD8rmDppqvxDeqVLQkSKsHSKsW0gPysQOvwiWSzj109PXyrsIUtsQyEAo0WG6h-sdqEtneHkGsWrHtNTZv__vND-Tp-GJyVp19mX47JHuYcEHqZSzYEdltFkv_DpOaxrxvXfg3c-78YA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkapeoAgQ5VEWiROS7XgfdoZbFBqVR6MIUaniYu2zRLRrK3Uu_HpmnZg6PVbybe2RrW_WM7P7zbeEfHCqVFJznRQFlIkQXCWgSkgK5jXPrRnzbin7bF6cnouvF_JicNRXR9o3epmGq-s0LH933Mrm2mQ9TyxbnE2LsQRgo6yxPntIHuGcZTAo1Dey3gJjH2z3MccFZ1kd1Q46enXKSvwrH5B9DJ4Fg7jwMQxKt5nmLk9yEHhmT8iv_pU3fJM_6brVqfl7R83xXt90SB5v01E62dzylDxw4Rlp0XfoVR0uaahDYuoY3uiP-YQuphP-iapA101cKKC1p8v2hsbY2LkvDlna91rS4d44VXjR2Osf6UArugy0if0m0YqJjrd6Ts5nJz-np8n2dIbEMMhFooBzg7m5taVzrJA-51KD9650xgospEbaMg0OcpDWMuaY8yCZsKrgCizwF2QPv8K9JNQBGG68yrU3Ud8NpMo9F9zLEZoQ8oh87OGpmo0IRxWLlwhrdQtr1cF6RN73AFY4VeL-hwquXt9UmMqWWA5CjgbLHWT_W41i27sjiFcnur3F59W9n3xH9hefZ9X3L_Nvr8kB5l0QWxpz9obstau1e4u5TauPOy_-B0Jf_uA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+long+non-coding+RNA+PCA3%3A+an+update+of+its+functions+and+clinical+applications+as+a+biomarker+in+prostate+cancer&rft.jtitle=Oncotarget&rft.au=Lemos%2C+Ana+Em%C3%ADlia+Goulart&rft.au=Matos%2C+Aline+da+Rocha&rft.au=Ferreira%2C+Luciana+Bueno&rft.au=Gimba%2C+Etel+Rodrigues+Pereira&rft.date=2019-11-12&rft.pub=Impact+Journals+LLC&rft.eissn=1949-2553&rft.volume=10&rft.issue=61&rft.spage=6589&rft.epage=6603&rft_id=info:doi/10.18632%2Foncotarget.27284&rft_id=info%3Apmid%2F31762940&rft.externalDBID=PMC6859920
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon